Gyre Therapeutics, Inc. Pre-Tax Income
Gyre Therapeutics, Inc. (GYRE) reported Pre-Tax Income of -$14.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-07
- Gyre Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$14.43M.
- Gyre Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$9.24M, a 299.29% decline year-over-year.
- Gyre Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$66.00K, a 108.55% decline year-over-year.
- Gyre Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was $7.63M, a 94.12% increase year-over-year.
- Gyre Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was $14.44M, a 37.82% decline from fiscal 2024.
- Gyre Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was $23.22M.
- Gyre Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$76.97M, a 917.73% decline from fiscal 2022.
- Gyre Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was $9.41M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$14.43M 10-Q · filed 2026-08-07 | -$32.46M 10-Q · filed 2026-08-07 | -$23.74M derived: sum of 3 quarters · filed 2026-08-07 | -$16.11M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | -$9.24M 10-Q · filed 2026-05-08 | -$9.30M derived: sum of 2 quarters · filed 2026-05-08 | -$1.67M derived: sum of 3 quarters · filed 2026-05-08 | -$3.25M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | -$66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $7.56M derived: sum of 2 quarters · filed 2026-03-13 | $5.99M derived: sum of 3 quarters · filed 2026-08-07 | $14.44M 10-K · filed 2026-03-13 | ||||
| 2025-09-30 | $7.63M 10-Q · filed 2025-11-07 | $6.05M derived: sum of 2 quarters · filed 2026-08-07 | $14.50M 10-Q · filed 2025-11-07 | $11.46M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | -$1.57M 10-Q · filed 2026-08-07 | $2.24M 10-Q · filed 2025-08-11 | $4.26M 10-Q · filed 2026-08-07 | $6.87M 10-Q · filed 2025-08-11 | $3.83M derived: sum of 3 quarters · filed 2026-08-07 | $7.76M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $4.63M 10-Q · filed 2026-05-08 | $5.41M derived: sum of 2 quarters · filed 2026-05-08 | $9.34M derived: sum of 3 quarters · filed 2026-05-08 | $15.37M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $772.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $4.70M derived: sum of 2 quarters · filed 2026-03-13 | $10.74M derived: sum of 3 quarters · filed 2026-03-13 | $23.22M 10-K · filed 2026-03-13 | ||||
| 2024-09-30 | $3.93M 10-Q · filed 2025-11-07 | $9.96M derived: sum of 2 quarters · filed 2025-11-07 | $22.45M 10-Q · filed 2025-11-07 | -$77.83M derived: sum of 4 quarters · filed 2025-11-07 | ||||
| 2024-06-30 | $6.04M 10-Q · filed 2025-08-11 | $18.52M 10-Q · filed 2025-08-11 | -$81.76M derived: sum of 3 quarters · filed 2025-08-11 | -$70.57M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | $12.48M 10-Q · filed 2025-05-09 | -$87.80M derived: sum of 2 quarters · filed 2025-05-09 | -$76.61M derived: sum of 3 quarters · filed 2025-05-09 | -$70.75M derived: sum of 4 quarters · filed 2025-05-09 | ||||
| 2023-12-31 | -$100.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$89.09M derived: sum of 2 quarters · filed 2025-03-17 | -$83.24M derived: sum of 3 quarters · filed 2025-03-17 | -$76.97M 10-K · filed 2025-03-17 | ||||
| 2023-09-30 | $11.19M 10-Q · filed 2024-11-13 | -$1.58M 10-Q · filed 2023-10-26 | $17.04M derived: sum of 2 quarters · filed 2024-11-13 | $23.31M 10-Q · filed 2024-11-13 | -$3.77M 10-Q · filed 2023-10-26 | $513.00K derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $5.85M 10-Q · filed 2024-08-13 | -$2.47M 10-Q · filed 2023-08-14 | $12.13M 10-Q · filed 2024-08-13 | -$2.20M 10-Q · filed 2023-08-14 | -$10.68M derived: sum of 3 quarters · filed 2024-08-13 | -$15.56M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $6.27M 10-Q · filed 2024-05-13 | $274.00K 10-Q · filed 2023-05-15 | -$16.53M derived: sum of 2 quarters · filed 2024-05-13 | -$21.41M derived: sum of 3 quarters · filed 2024-05-13 | $30.22M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | -$22.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$27.68M derived: sum of 2 quarters · filed 2024-03-27 | $23.95M derived: sum of 3 quarters · filed 2024-03-27 | $9.41M 10-K · filed 2024-03-27 | -$7.89M 10-K · filed 2023-03-30 | |||
| 2022-09-30 | -$4.88M 10-Q · filed 2023-10-26 | $46.75M derived: sum of 2 quarters · filed 2023-10-26 | $32.21M 10-Q · filed 2023-10-26 | |||||
| 2022-06-30 | $51.63M 10-Q · filed 2023-08-14 | $37.10M 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | -$14.54M 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | -$87.93M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |